Coiled Advances Next-Generation AO-252 Formulation

AI SummaryClose X

Coiled Therapeutics plc is advancing its next-generation oral formulation of AO-252, a TACC3 inhibitor, with the first patient dosing expected in July 2026. This new lipid-based softgel formulation is designed to optimize drug exposure and achieve more consistent, dose-proportional absorption compared to the current tablet formulation, which has shown dose-dependent absorption limitations. The company highlights recent Phase I data showing an 80% Clinical Benefit Rate with twice-daily dosing of the current tablet formulation in patients with ovarian and endometrial cancer, providing the rationale for the improved softgel design. This development supports the company's transition to dose expansion cohorts in ovarian and prostate cancer, targeting up to 30 patients by Q4 2026, with comprehensive data readouts anticipated in the second half of 2026.

Disclaimer*

UK 100

Latest directors dealings